Press releases

Fighting respiratory diseases, particularly in hospitals Montréal, Canada – October 8, 2025 – Glycovax Pharma today announced a strategic collaboration with the National Research Council of Canada (NRC) and the Faculty of Veterinary Medicine at the Université de Montréal to develop a glycoconjugate vaccine against Pseudomonas aeruginosa (Pa) infections. Funding for this project is made…

Montreal, Canada, August 18, 2025 – Pseudomonas aeruginosa (Pa) is a bacterium responsible for nosocomial infections and is often fatal when contracted by people living with cystic fibrosis. There is currently no vaccine to prevent Pa-related infections even though this bacterium is a high-priority target for the World Health Organization (WHO). The National Research Council…

MONTREAL, Canada July 8, 2025 – Glycovax Pharma Inc. is taking an important step forward in its contribution to the vaccine industry with the large-scale production of sulfated lactosyl archaeol (SLA) archaeosomes, a new glycolipidic vaccine adjuvant developed by the National Research Council of Canada (NRC). This NRC license represents a major strategic development for…

Montreal, Canada, June 9, 2025 – Glycovax Pharma Inc. has begun large-scale biomanufacturing of the CRM197 protein for use in numerous conjugate vaccines for human and animal vaccines. The National Research Council of Canada (NRC) has developed a unique and highly efficient production system for CRM197. Glycovax has refined its production to meet regulatory requirements…